Exodus Point Capital Management, LP Gritstone Bio, Inc. Transaction History

Exodus Point Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$2.13 - $3.74 $38,731 - $68,008	18,184 New	18,184 $51,000
Q3 2022 Nov 10, 2022	SELL	$2.46 - $4.75 $27,099 - $52,326	-11,016 Closed	0 $0
Q2 2022 Aug 19, 2022	SELL	$1.77 - $4.34 $361,632 - $886,714	-204,312 Reduced 94.88%	11,016 $27,000
Q1 2022 May 13, 2022	BUY	$4.03 - $12.19 $867,771 - $2.62 Million	215,328 New	215,328 $887,000
Q3 2021 Nov 15, 2021	SELL	$6.41 - $13.54 $83,926 - $177,279	-13,093 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$8.13 - $10.2 $22,764 - $28,559	-2,800 Reduced 17.62%	13,093 $120,000
Q1 2021 May 17, 2021	SELL	$4.07 - $27.11 $55,832 - $371,894	-13,718 Reduced 46.33%	15,893 $150,000
Q4 2020 Feb 16, 2021	BUY	$2.57 - $4.22 $76,100 - $124,958	29,611 New	29,611 $117,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.